The pharmacology of leishmaniasis

Gen Pharmacol. 1998 Apr;30(4):435-43. doi: 10.1016/s0306-3623(97)00268-1.

Abstract

The development of new strategies on chemotherapy of parasitic protozoan diseases is one of the most exciting research fields of recent years. World Health Organization (WHO) reports have recognized that the physiology and biochemistry of protozoan parasites and the host-parasite relation are the main targets for the design of new drugs that can be used in the future against these diseases.

Publication types

  • Review

MeSH terms

  • Allopurinol / chemistry
  • Allopurinol / therapeutic use
  • Amphotericin B / chemistry
  • Amphotericin B / therapeutic use
  • Animals
  • Antiprotozoal Agents / chemistry
  • Antiprotozoal Agents / therapeutic use*
  • Drug Design
  • Humans
  • Itraconazole / chemistry
  • Itraconazole / therapeutic use
  • Ketoconazole / chemistry
  • Ketoconazole / therapeutic use
  • Leishmania / drug effects*
  • Leishmania / metabolism
  • Leishmaniasis / drug therapy*
  • Leishmaniasis / metabolism
  • Leishmaniasis / parasitology
  • Paromomycin / chemistry
  • Paromomycin / therapeutic use
  • World Health Organization

Substances

  • Antiprotozoal Agents
  • Itraconazole
  • Paromomycin
  • Allopurinol
  • Amphotericin B
  • Ketoconazole